**Core Concept**
Insulinoma is a rare tumor of the pancreas that produces excess insulin, leading to hypoglycemia. The medical management of insulinoma involves controlling blood glucose levels and preventing hypoglycemic episodes.

**Why the Correct Answer is Right**
The primary goal of medical management is to suppress insulin secretion and maintain normoglycemia. This can be achieved with diazoxide, a potassium channel activator that inhibits insulin release from the alpha cells of the pancreas, thereby reducing insulin secretion. **Octreotide**, a synthetic somatostatin analogue, can also be used to inhibit insulin secretion and reduce symptoms. **Glucagon** can be administered to manage acute hypoglycemic episodes.

**Why Each Wrong Option is Incorrect**
**Option A:** **Glipizide** is a sulfonylurea that stimulates insulin release and is contraindicated in insulinoma.
**Option B:** **Metformin** can worsen hypoglycemia by increasing insulin sensitivity and is not recommended for insulinoma.
**Option C:** **Pioglitazone** is a thiazolidinedione that increases insulin sensitivity and can worsen hypoglycemia in insulinoma.

**Clinical Pearl / High-Yield Fact**
In insulinoma, diazoxide is the first-line medical management option to control hypoglycemia and prevent acute episodes. However, the definitive treatment is surgical resection of the tumor.

**Correct Answer:** C. Octreotide is used to manage insulinoma by inhibiting insulin secretion.